Diffuse large B-cell lymphoma
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …
[HTML][HTML] Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
Background The prognosis of patients with early relapsed or refractory large B-cell
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …
lymphoma after the receipt of first-line chemoimmunotherapy is poor. Methods In this …
[HTML][HTML] Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
H Tilly, F Morschhauser, LH Sehn… - … England Journal of …, 2022 - Mass Medical Soc
Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm …
Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-cell …
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
Background Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor
(CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a …
(CAR) T-cell therapy. In the previous analysis of the ZUMA-1 registrational study, with a …
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …
lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up …
Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma
Purpose Outcomes for patients with diffuse large B-cell lymphoma remain heterogeneous,
with existing methods failing to consistently predict treatment failure. We examined the …
with existing methods failing to consistently predict treatment failure. We examined the …